Effect of Crocus sativus Extract Supplementation in the Metabolic Control of People with Diabetes Mellitus Type 1: A Double-Blind Randomized Placebo-Controlled Trial
-
Published:2024-06-29
Issue:13
Volume:16
Page:2089
-
ISSN:2072-6643
-
Container-title:Nutrients
-
language:en
-
Short-container-title:Nutrients
Author:
Giannoulaki Parthena12ORCID, Kotzakioulafi Evangelia2ORCID, Nakas Alexandros2, Kontoninas Zisis2, Karlafti Eleni2ORCID, Evripidou Polykarpos2, Kantartzis Konstantinos345ORCID, Savopoulos Christos2, Chourdakis Michail6ORCID, Didangelos Triantafyllos2ORCID
Affiliation:
1. Department of Clinical Nutrition, University General Hospital of Thessaloniki AHEPA, 54636 Thessaloniki, Greece 2. Diabetes Center, 1st Propaedeutic Department of Internal Medicine, School of Medicine, University General Hospital of Thessaloniki AHEPA, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece 3. Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, 72076 Tübingen, Germany 4. Institute for Diabetes Research and Metabolic Diseases (IDM), Helmholtz Centre Munich, University of Tübingen, 72076 Tübingen, Germany 5. German Center for Diabetes Research (DZD), 72076 Tübingen, Germany 6. Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Abstract
Introduction–Background: Data from experimental trials show that Crocus sativus L. (saffron) is considered to improve glycemia, lipid profile, and blood pressure and reduce oxidative stress. So far, clinical trials have been conducted in individuals with metabolic syndrome and Diabetes Mellitus type 2 (DMT-2). The purpose of this study is to assess the effectiveness of saffron in individuals with Diabetes Mellitus type 1 (DMT-1). Patients–Methods: 61 individuals with DMT-1, mean age 48 years old (48.3 ± 14.6), 26 females (42.6%) were randomized to receive a new oral supplement in sachets containing probiotics, prebiotics, magnesium, and Crocus sativus L. extract or placebo containing probiotics, prebiotics and magnesium daily for 6 months. Glycemic control was assessed with a continuous glucose monitoring system and laboratory measurement of HbA1c and lipid profile was also examined. Blood pressure at baseline and end of intervention was also measured. Individuals were either on a continuous subcutaneous insulin infusion with an insulin pump or in multiple daily injection regimens. Diabetes distress and satiety were assessed through a questionnaire and body composition was assessed with bioelectrical impedance. Results: At the end of the intervention, the two groups differed significantly only in serum triglycerides (p = 0.049). After 6 months of treatment, a significant reduction in the active group was observed in glycated hemoglobin (p = 0.046) and serum triglycerides (p = 0.021) compared to baseline. The other primary endpoints (glycemic control, lipid profile, blood pressure) did not differ within the groups from baseline to end of intervention, and there was no significant difference between the two groups. Diabetes distress score improved significantly only in the active group (p = 0.044), suggesting an overall improvement in diabetes disease burden in these individuals but that was not significant enough between the two groups. Conclusions: A probiotic supplement with saffron extract improves serum triglycerides in well-controlled people with DMT-1 and may potentially be a valuable adjunct for enhancing glycemic control.
Reference51 articles.
1. American Diabetes Association Professional Practice Committee, ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Ekhlaspour, L., Gaglia, J.L., Hilliard, M.E., and Johnson, E.L. (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care, 47, S20–S42. 2. González, P., Lozano, P., Ros, G., and Solano, F. (2023). Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int. J. Mol. Sci., 24. 3. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016). Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-Up. Diabetes Care, 39, 686–693. 4. HYPOS-1 Study Group of AMD, Giorda, C.B., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F.M., Lucisano, G., and Nicolucci, A. (2015). Incidence and Risk Factors for Severe and Symptomatic Hypoglycemia in Type 1 Diabetes. Results of the HYPOS-1 Study. Acta Diabetol., 52, 845–853. 5. Therapies for Hyperglycaemia-Induced Diabetic Complications: From Animal Models to Clinical Trials;Calcutt;Nat. Rev. Drug Discov.,2009
|
|